Abstract:This work presents a cost‐effective, advanced TMT‐labeling protocol for large‐scale toxicological screenings, emphasizing its benefits in addressing the common limitations in proteomics, for example, time, cost, and biological material requirements. As proof‐of‐concept, the protocol is assessed by studying the cellular effects of nine well‐characterized benchmark nanomaterials on lung human epithelial A549 cells, with a comparative analysis to a traditional proteomic method. Proteomic investigations yield high‐dimensional datasets, yet their application to large‐scale toxicological assessments is hindered by reproducibility challenges due to fluctuating measurement conditions. To address these limitations, this study introduces an advanced tandem mass tag (TMT) labeling protocol. Although labeling approaches shorten data acquisition time by multiplexing samples compared to traditional label‐free quantification (LFQ) methods in general, the associated costs may surge significantly with large sample sets, for example, in toxicological screenings. However, the introduced advanced protocol offers an efficient, cost‐effective alternative, reducing TMT reagent usage (by a factor of ten) and requiring minimal biological material (1 μg), while demonstrating increased reproducibility compared to LFQ. To demonstrate its effectiveness, the advanced protocol is employed to assess the toxicity of nine benchmark nanomaterials (NMs) on A549 lung epithelial cells. While LFQ measurements identify 3300 proteins, they proved inadequate to reveal NM toxicity. Conversely, despite detecting 2600 proteins, the TMT protocol demonstrates superior sensitivity by uncovering alterations induced by NM treatment. In contrast to previous studies, the introduced advanced protocol allows simultaneous and straightforward assessment of multiple test substances, enabling prioritization, ranking, and grouping for hazard evaluation. Additionally, it fosters the development of New Approach Methodologies (NAMs), contributing to innovative methodologies in toxicological research.

Efficacy of a Modified Sequential Therapy Including Bismuth Subcitrate as First‐Line Therapy to Eradicate Helicobacter pylori in a Turkish Population

The liver toxicity biomarker study: phase I design and preliminary results.

Proteomic analysis of acetaminophen-induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury

Diversity Characteristics of the 2008-2009 Pharmacy College Application Service Applicant Pool

Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved

Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs

Hepatotoxic evaluation of toosendanin via biomarker quantification and pathway mapping of large-scale chemical proteomics

Clinical evaluation of clopamide (Brinaldix) in inpatients and outpatients.

Towards an Energy-Proportional Storage System using a Cluster of Wimpy Nodes

Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions

Pharmacoproteomic profiling identifies secreted markers for aberrant drug action

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury

Transcriptional profiling of drug-induced liver injury biomarkers: association of hepatic Srebf1/Pparα signaling and crosstalk of thrombin, alcohol dehydrogenase, MDR and DNA damage regulators

Advancing Nanomaterial Toxicology Screening Through Efficient and Cost‐Effective Quantitative Proteomics

Preventable obstetrical interventions: how many caesarean sections can be prevented in Canada?

Risk Assessment for Hepatobiliary Toxicity Liabilities in Drug Development

Paradigm shift in biomarker translation: a pipeline to generate clinical grade biomarker candidates from DIA-MS discovery

Proteomic Identification of Potential Susceptibility Factors in Drug-Induced Liver Disease.

A Proteomics Pipeline for Generating Clinical Grade Biomarker Candidates from Data‐Independent Acquisition Mass Spectrometry (DIA‐MS) Discovery

The current state of serum biomarkers of hepatotoxicity